Impact of 21st Century Cures Act on Breakpoints and Commercial Antimicrobial Susceptibility Test Systems: Progress and Pitfalls.
J Clin Microbiol
; 56(5)2018 05.
Article
em En
| MEDLINE
| ID: mdl-29436415
ABSTRACT
Antimicrobial resistance is the most pressing medical challenge of the past decade. At the front line are clinical laboratories, which are responsible for accurately reporting antimicrobial susceptibility test (AST) results to clinicians and public health authorities. The ability of the laboratory to detect resistance has been hampered by several factors. In 2016, the 21st Century Cures Act was signed into law, marking an important step toward resolving many regulatory dilemmas that hampered development and updates to commercial AST systems (cASTs). We describe the pathway and history of U.S. regulation of cASTs and outline both the rewards and unmet needs possible from the 21st Century Cures Act.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Testes de Sensibilidade Microbiana
/
Testes Diagnósticos de Rotina
/
Política de Saúde
/
Antibacterianos
Tipo de estudo:
Prognostic_studies
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article